Founded by Lovisa Afzelius, Metaphore Biotechnologies, where are unlocking the secrets of nature's mimicry to revolutionize biotechnology research. With an impressive $50M raised and investment from Flagship Pioneering, their focus lies in driving unprecedented insights into molecular interactions through their groundbreaking MIMiC™ platform. Just as organisms gain adaptive advantages by imitating others, they harness the power of biomimicry to design new molecules precisely tuned for therapeutic benefit. Inspired by the owl butterfly, which mimics the appearance of an owl's eye for protection, we have adapted this concept to drug discovery. 

Their computationally driven bioplatform, MIMiC™, engineers therapeutics that trigger desired biological responses, surpassing the limitations of current drugs. Founded in 2021, they strive to unlock breakthroughs that outperform existing treatments and bring hope to patients with limited therapeutic options. With their strengths in unlocking intractable targets, designing drugs for function, defining therapeutics' specificity, and creating modality-agnostic mimics, they are at the forefront of transforming the biotechnology landscape. Join them on this extraordinary journey as they reshape the future of therapeutics.